Umbrella Review on Non-Statin Lipid-Lowering Therapy

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

(2020) Sotirios Tsimikas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia

(2020) Vasilios G. Athyros et al.   Current Vascular Pharmacology

PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL

(2020) Brian Bergmark et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile

(2020) Emir Muzurović et al.   EXPERT OPINION ON PHARMACOTHERAPY

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evinacumab in Patients with Refractory Hypercholesterolemia

(2020) Robert S. Rosenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

(2019) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

(2019) Deepak L. Bhatt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary

(2019) Donna K. Arnett et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipid-Lowering Agents

(2019) Robert A. Hegele et al.   CIRCULATION RESEARCH

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

(2019) Veronica J Alexander et al.   EUROPEAN HEART JOURNAL

CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins?

(2019) Xiaoming Jia et al.   Journal of the American Heart Association

Impact of ADCY9 Genotype on Response to Anacetrapib

(2019) Jemma C. Hopewell et al.   CIRCULATION

Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)

(2019) Daniel Gaudet et al.   AMERICAN JOURNAL OF CARDIOLOGY

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

(2019) Zahid Ahmad et al.   CIRCULATION

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association

(2019) Ann C. Skulas-Ray et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

(2019) Anne C. Goldberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk

(2018) Steve Yadlowsky et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

(2018) Christie M. Ballantyne et al.   ATHEROSCLEROSIS

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

(2018) Shun Ishibashi et al.   Journal of Clinical Lipidology

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial

(2018) Stephen J. Nicholls et al.   CLINICAL CARDIOLOGY

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

(2018) Aruna D. Pradhan et al.   AMERICAN HEART JOURNAL

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

(2018) Scott M. Grundy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab Reduces Fatal and Nonfatal Cardiovascular Events

(2018) Michael Szarek et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lomitapide for the treatment of hypercholesterolemia

(2017) Amanda J. Berberich et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lipid Lowering Therapy and Circulating PCSK9 Concentration

(2017) Tsuyoshi Nozue   Journal of Atherosclerosis and Thrombosis

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2017) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

(2017) Marc S Sabatine et al.   Lancet Diabetes & Endocrinology

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus

(2017) Robert P. Giugliano et al.   CIRCULATION

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

(2016) Ozlem Bilen et al.   Current Atherosclerosis Reports

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia

(2016) Genovefa D Kolovou et al.   Journal of Atherosclerosis and Thrombosis

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy

(2015) Carlos Aguiar et al.   ATHEROSCLEROSIS SUPPLEMENTS

Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

(2015) Preethi Mani et al.   Current Atherosclerosis Reports

Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention

(2015) Bryan A. Smith et al.   Current Atherosclerosis Reports

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Safety and efficacy of ezetimibe: A meta-analysis

(2015) Gianluigi Savarese et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial

(2014) Karen L. Margolis et al.   DIABETES CARE

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Statin Toxicity From Macrolide Antibiotic Coprescription

(2013) Amit M. Patel et al.   ANNALS OF INTERNAL MEDICINE

Discontinuation of Statins in Routine Care Settings

(2013) Huabing Zhang et al.   ANNALS OF INTERNAL MEDICINE

Colesevelam: A New and Improved Bile Acid Sequestrant?

(2013) Konstantinos Tziomalos et al.   CURRENT PHARMACEUTICAL DESIGN

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

(2013) Gregory S. Thomas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina

(2012) Tadaaki Arimura et al.   Journal of Cardiology

Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery

(2012) George N. Kouvelos et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PPARα Agonists Fenofibrate and CP-778875 Cause Increased β-Oxidation, Leading to Oxidative Injury in Skeletal and Cardiac Muscle in the Rat

(2012) John C. Pettersen et al.   TOXICOLOGIC PATHOLOGY

Mipomersen, an antisense apolipoprotein B synthesis inhibitor

(2011) Damon A Bell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

(2011) Colin Baigent et al.   LANCET